Acadia Pharmaceuticals (ACAD) Revenue Growth (5y) (2015 - 2026)
Acadia Pharmaceuticals (ACAD) Revenue Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - |
| 3 | Akari Therapeutics | 1,045.06 Bn | 1,045.06 Bn | - |
| 4 | BeOne Medicines | 470.64 Bn | 465.84 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.91 Bn | 115.67 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.07 Bn | 61.31 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.77 Bn | 62.77 Bn | - |
| 8 | Argenx Se | 56.21 Bn | 51.02 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.60 Bn | 37.60 Bn | - |
| 10 | Acadia Pharmaceuticals | 4.31 Bn | 3.45 Bn | 243.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 20.26% |
| Dec 31, 2025 | 18.60% |
| Sep 30, 2025 | 18.24% |
| Jun 30, 2025 | 19.16% |
| Mar 31, 2025 | 22.09% |
| Dec 31, 2024 | 21.43% |
| Sep 30, 2024 | 21.50% |
| Jun 30, 2024 | 23.80% |
| Mar 31, 2024 | 26.73% |
| Dec 31, 2023 | 31.14% |
| Sep 30, 2023 | 29.42% |
| Jun 30, 2023 | 23.69% |
| Mar 31, 2023 | 19.37% |
| Dec 31, 2022 | 25.66% |
| Sep 30, 2022 | 29.73% |
| Jun 30, 2022 | 34.58% |
| Mar 31, 2022 | 49.84% |
| Dec 31, 2021 | 61.34% |
| Sep 30, 2021 | 90.34% |
| Jun 30, 2021 | 312.05% |